patient subgroup...
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
potential COVID-19 treatments - versus standard of care - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.95 [0.91, 1.00]< 1 14% 71 studies (70/1) 98.2 % moderate critical moderate crucial - death or transfer to ICU 0.98 [0.85, 1.12]< 1 61% 5 studies (4/1) 63.6 % low not evaluable high crucial - deaths 0.73 [0.63, 0.85]< 1 95% 150 studies (139/11) 100.0 % moderate critical moderate crucial - deaths (time to event analysis only) 0.77 [0.54, 1.11]< 1 99% 26 studies (23/3) 91.8 % moderate critical moderate crucial - clinical deterioration 0.80 [0.69, 0.93]< 1 0% 26 studies (24/2) 99.8 % moderate low moderate important - clinical improvement 1.28 [1.11, 1.47]> 1 53% 33 studies (31/2) 100.0 % moderate low moderate important - clinical improvement (14-day) 1.17 [0.97, 1.41]> 1 55% 22 studies (22/-) 94.7 % some concern low moderate important - clinical improvement (21-day) 2.09 [0.04, 119.96]> 1 0% 1 study (1/-) 63.7 % NA not evaluable important - clinical improvement (28-day) 1.37 [1.07, 1.74]> 1 62% 12 studies (11/1) 99.4 % moderate critical moderate important - clinical improvement (7-day) 1.36 [1.10, 1.68]> 1 38% 14 studies (13/1) 99.8 % moderate low moderate important - clinical improvement (time to event analysis only) 1.27 [1.11, 1.46]> 1 37% 15 studies (15/-) 100.0 % some concern critical moderate important - death or ventilation 0.95 [0.90, 1.00]< 1 61% 22 studies (22/-) 96.7 % some concern low moderate important - hospital discharge 1.08 [1.00, 1.16]> 1 83% 23 studies (17/6) 97.9 % moderate critical moderate important - mechanical ventilation 0.87 [0.79, 0.96]< 1 30% 47 studies (46/1) 99.8 % moderate critical moderate important - mechanical ventilation (time to event analysis only) 0.65 [0.25, 1.70]< 1 60% 3 studies (3/-) 81.0 % some concern not evaluable moderate important - radiologic improvement (14-day) 2.13 [1.30, 3.50]> 1 21% 6 studies (6/-) 99.9 % some concern not evaluable moderate important - radiologic improvement (7-day) 0.40 [0.02, 6.97]> 1 77% 3 studies (3/-) 26.9 % some concern not evaluable moderate important - viral clearance 2.02 [1.31, 3.11]> 1 75% 19 studies (18/1) 99.9 % moderate low moderate important - viral clearance (time to event analysis only) 1.07 [0.83, 1.38]> 1 61% 8 studies (5/3) 69.1 % serious not evaluable low important - viral clearance by day 14 0.94 [0.54, 1.63]> 1 90% 18 studies (15/3) 41.2 % serious low low important - viral clearance by day 7 1.43 [1.08, 1.90]> 1 66% 14 studies (14/-) 99.3 % some concern low moderate important - ICU admission 0.70 [0.53, 0.92]< 1 56% 26 studies (24/2) 99.4 % moderate critical moderate non important - off oxygenation 8.57 [1.43, 51.36]> 1 0% 1 study (1/-) 99.0 % NA not evaluable non important - recovery 1.17 [1.02, 1.35]> 1 0% 5 studies (5/-) 98.7 % some concern not evaluable moderate non important - 00 cardiac arrest 1.92 [0.35, 10.49]< 1 0% 1 study (1/-) 22.7 % NA not evaluable important - related SAE (TRSAE) 1.24 [0.50, 3.11]< 1 0% 1 study (1/-) 32.0 % NA not evaluable important - serious adverse events 1.15 [1.01, 1.31]< 1 0% 31 studies (31/-) 1.6 % some concern low moderate important - superinfection 0.77 [0.06, 9.89]< 1 76% 2 studies (2/-) 57.8 % high not evaluable low important - acute kidney injury 0.74 [0.28, 1.99]< 1 42% 2 studies (1/1) 72.4 % low not evaluable high non important - adverse events 1.62 [1.34, 1.97]< 1 44% 26 studies (26/-) 0.0 % some concern critical moderate non important - arrhythmia 0.73 [0.29, 1.80]< 1 32% 4 studies (3/1) 75.5 % moderate not evaluable moderate non important - elevated liver enzymes 1.37 [0.21, 8.85]< 1 86% 2 studies (1/1) 37.0 % low not evaluable high non important - long QT 2.39 [0.24, 23.87]< 1 80% 2 studies (2/-) 23.0 % some concern not evaluable moderate non important - Myocardial infarction 0.87 [0.19, 3.92]< 1 0% 1 study (-/1) 57.2 % NA not evaluable non important - renal impairment 1.43 [1.00, 2.05]< 1 0% 2 studies (2/-) 2.5 % some concern not evaluable moderate non important - severe adverse events 1.00 [0.02, 51.70]< 1 0% 1 study (1/-) 50.0 % NA not evaluable non important - venous thromboembolism 5.23 [0.42, 65.62]< 1 0% 1 study (-/1) 10.2 % NA not evaluable non important - 00 Thromboembolic events 0.89 [0.31, 2.55]< 1 0% 1 study (1/-) 58.6 % NA not evaluable non important -
LoD: level of statistical demonstration:
